Company Overview

Rocket Pharmaceuticals, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing gene therapies for rare and life-threatening diseases. The company operates within the biotechnology and pharmaceutical industries, with a specialization in in vivo adeno-associated virus (AAV) and ex vivo lentiviral vector (LV) gene therapy platforms. Its primary objective is to address diseases with high unmet medical need through potentially curative, one-time treatments.

The company’s revenue model is primarily driven by research and development activities rather than commercial product sales, as its programs remain in clinical development. Rocket Pharmaceuticals targets pediatric and adult patients affected by rare genetic disorders, particularly those involving cardiac, metabolic, and immunologic dysfunctions. Founded in 1999 and later restructured and renamed Rocket Pharmaceuticals, the company has evolved through acquisitions and pipeline expansion to build a diversified portfolio of gene therapy candidates.

Business Operations

Rocket Pharmaceuticals organizes its operations around two core therapeutic platforms: AAV-based gene therapy programs and LV-based gene therapy programs. These platforms support multiple clinical-stage candidates targeting inherited cardiac conditions, metabolic disorders, and bone marrow–derived diseases. The company’s activities include vector design, preclinical research, clinical development, and regulatory engagement, with manufacturing supported through a combination of internal capabilities and third-party partners.

Operations are primarily based in the United States, with clinical trials conducted both domestically and internationally. Rocket Pharmaceuticals controls key gene therapy intellectual property and maintains wholly owned subsidiaries that support research and development activities. The company does not currently report commercial revenue and funds operations primarily through equity financing and strategic capital raises.

Strategic Position & Investments

Strategically, Rocket Pharmaceuticals aims to establish itself as a leading developer of gene therapies for rare diseases by advancing multiple programs in parallel and leveraging platform-based efficiencies. Growth initiatives focus on progressing late-stage clinical candidates, expanding manufacturing readiness, and pursuing regulatory approvals in major markets. The company has historically used acquisitions of early-stage assets and technology platforms to strengthen its pipeline rather than acquiring revenue-generating businesses.

Rocket Pharmaceuticals maintains a portfolio of wholly owned development programs rather than a diversified external investment portfolio. Its strategic emphasis includes emerging gene therapy technologies, long-term expression durability, and safety optimization. While collaborations with academic institutions and contract development organizations are central to its model, no material joint ventures have been publicly established as independent operating entities.

Geographic Footprint

Rocket Pharmaceuticals is headquartered in the United States, with its principal executive offices in New Jersey. The company’s operational footprint is primarily concentrated in North America, where corporate management, research oversight, and regulatory strategy are based.

Internationally, Rocket Pharmaceuticals has a presence through clinical trial sites in Europe and other global regions, reflecting the rare-disease patient populations required for development. While it does not operate large-scale commercial facilities abroad, its international activities support clinical development, regulatory engagement, and future market access in Europe and other major healthcare markets.

Leadership & Governance

Rocket Pharmaceuticals is led by an executive team with experience in biotechnology, rare diseases, and gene therapy development. The leadership’s strategic vision emphasizes scientific rigor, patient-focused development, and long-term value creation through potentially curative therapies.

Key executives include:

• Gaurav Shah, M.D. – Chief Executive Officer
• Kinnari Patel – President and Chief Operating Officer
• Peter C. Traber, M.D. – Chairman of the Board

Public disclosures consistently identify these individuals in senior leadership roles; however, details on certain executive positions, including finance leadership, vary across public sources. Where discrepancies exist, data is inconclusive based on available public sources.